IMI2 - Call 21: Combatting coronavirus infections

The Innovative Medicines Initiative (IMI) is currently promoting a call under the topic of “Development of therapeutics and diagnostics combatting coronavirus infections”.

According to the call text shared: “Proposals submitted under this topic are expected to advance our knowledge of SARS-CoV-2 specifically and the wider coronavirus family in general with the aim of contributing to an efficient patient management and/or public health preparedness and response to current and future outbreaks of coronavirus infection.”

Below, you can find the most relevant information about the call and application process:

IMI2 - Call 21 - https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-21

• Call ID: H2020-JTI-IMI2-2020-21-single-stage
• Action Type: RIA – Research and Innovation Actions
• Indicative budged
  • From EFPIA companies and IMI2 Associated Partners: to be defined based upon selected proposals
  • From the IMI2 JU: EUR 45 000 000 (All proposals submitted under this Call and evaluated above the threshold will be ranked in one single list. Proposals will be invited in order of ranking to prepare a Grant Agreement within the limits of the available overall budget.)
• Deadline: 31 March 2020

IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

You can visit IMI's website here: https://www.imi.europa.eu/

Posted by Mariana Marques on 25-Mar-2020 17:42